Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ultragenyx Pharmaceutical (RARE) Asset Utilization Ratio (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Asset Utilization Ratio for 10 consecutive years, with 0.49 as the latest value for Q4 2025.

  • On a quarterly basis, Asset Utilization Ratio rose 34.26% to 0.49 in Q4 2025 year-over-year; TTM through Dec 2025 was 0.49, a 34.26% increase, with the full-year FY2025 number at 0.44, up 18.56% from a year prior.
  • Asset Utilization Ratio was 0.49 for Q4 2025 at Ultragenyx Pharmaceutical, down from 0.5 in the prior quarter.
  • In the past five years, Asset Utilization Ratio ranged from a high of 0.5 in Q3 2025 to a low of 0.2 in Q1 2021.
  • A 5-year average of 0.31 and a median of 0.31 in 2024 define the central range for Asset Utilization Ratio.
  • Peak YoY movement for Asset Utilization Ratio: soared 93.45% in 2021, then dropped 2.61% in 2022.
  • Ultragenyx Pharmaceutical's Asset Utilization Ratio stood at 0.23 in 2021, then dropped by 1.73% to 0.23 in 2022, then surged by 38.48% to 0.32 in 2023, then rose by 15.79% to 0.37 in 2024, then skyrocketed by 34.26% to 0.49 in 2025.
  • Per Business Quant, the three most recent readings for RARE's Asset Utilization Ratio are 0.49 (Q4 2025), 0.5 (Q3 2025), and 0.47 (Q2 2025).